Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer

Anticancer Res. 2013 Oct;33(10):4591-4.

Abstract

AIM/ BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR), a combined indicator of inflammation and immunology, is as yet unidentified regarding the clinical outcome of stage II and III colon cancer patients. We evaluated the effect of NLR on time-to-recurrence (TTR) and overall survival (OS) in selected patients.

Patients and methods: A total of 504 patients with stage II and III colon cancer were included in this retrospective study. Preoperative NLR with a cut-off level of 4 was associated with TTR and OS.

Results: In univariate analysis, elevated NLR was significantly associated with decreased TTR (p=0.001) and remained significant in multivariate analysis (p=0.006). Patients with NLR >4 showed a median TTR of 62.2 months. In contrast, patients with NLR ≤ 4 had a median TTR of 92.6 months.

Conclusion: This study suggests that preoperative NLR may be an independent prognostic marker for TTR in stage II and III colon cancer patients.

Keywords: Neutrophil-to-lymphocyte ratio; colon cancer.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Colonic Neoplasms / immunology*
  • Colonic Neoplasms / mortality
  • Colonic Neoplasms / pathology
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymphocyte Count
  • Lymphocytes / immunology*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Staging
  • Neutrophils / immunology*
  • Preoperative Period
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Treatment Outcome